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Introduction
Our ICU is a general mixed ICU with 9 beds in a
trauma centre. We admit over 300 patients/year. We
have started using thromboelastometry (ROTEM) in
2009. Thromboelastometry is used to guide the therapy
of massive bleeding and therapy of coagulopathy in ICU
patients. The usage of thromboelastometry has been
increasing since 2009 and in January 2014 we have
implemented POC thromboelastometry guided factor
concentrate based coagulation algorithm for the treat-
ment of coagulopathy in massive bleeding [1].
Objectives
Analysis of transfusion requirements of packed red
blood cells (PRBC), plasma (FFP), platelet concentrates
and the usage of fibrinogen and prothrombin complex
concentrate (PCC) in ICU patients before and after the
introduction of thromboelastometry guided factor con-
centrate based coagulation algorithm for the treatment
of coagulopathy in massive bleeding and its influence on
cost of therapy.
Methods
Retrospective analysis of the utilisation of blood pro-
ducts (PRBC,FFP, platelet concentrates in therapeutic
doses) and fibrinogen and PCC before and after the
introduction of thromboelastometry guided factor con-
centrate based coagulation algorithm.
Results
The usage of all allogenic blood products has decreased
in our unit after the introduction of thromboelastometry
guided factor concentrate based coagulation algorithm
by 46,7%.
The reduction of PRBC was 16,6%, platelet concentrate
usage decreased by 43,6 % and FFP usage decreased
by 81,8%.
The usage of fibrinogen and PCC has increased after
the implementation of algorithm.
The cost of therapy of bleeding and coagulopathy in
our ICU (cost of PRBC, FFP, platelet concentrates,
fibrinogen and PCC) has not significantly changed after
the implementation of algorithm.
Conclusions
We have achieved a major reduction in allogenic blood
products after the introduction of a thromboelastometry
guided factor concentrate based coagulation algorithm
in our intensive care unit. The usage of fibrinogen and
PCC has increased, but the cost has not significantly
changed. Implementation of thromboelastometry guided
factor concentrate based coagulation algorithm reduces
the exposure of intensive care patients to allogenic
blood products and does not increase cost of therapy of
bleeding and coagulopathy.
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Figure 1 evolution of usage of all blood products in time.
Figure 2 evolution in usage of PRBC,FFP and platelets.
Table 1
fibrinogen (g) PCC (doses)
2013 146 91
2014 257 128
[usage of fibrinogen and PCC]
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